https://www.targetedonc.com/view/results-from-the-phase-3-nrg-rtog-1112-study-of-sorafenib-in-hcc
Laura A. Dawson, MD, FRCPC, discusses findings from the NRG/RTOG 1112 study of stereotactic body radiation therapy followed by sorafenib vs sorafenib alone in hepatocellular carcinoma.
Create an account or login to join the discussion